Women's Health Initiative Cancer Survivor Cohort

妇女健康倡议癌症幸存者队列

基本信息

批准号：
9207126
负责人：
GARNET L. ANDERSON
金额：
$ 226.07万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-02-15 至 2019-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9207126
关键词：
Address Aging Algorithms Biological Markers Blood specimen Breast Cancer Burden Cancer Research Network Cancer Survivor Cancer Survivorship Chronic Disease Clinical Colorectal Colorectal Cancer Comorbidity Coupled DNA Data Data Collection Data Set Databases Diagnosis Endometrial Endometrial Carcinoma Ensure Epidemiologic Factors Epidemiological Factors Genetic Markers Health Health Maintenance Organizations Incidence Intervention Laboratories Length Lung Lymphoma Lymphoma Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of ovary Medical Records Medicare Methods Molecular Outcome Ovarian Paraffin Embedding Patient Outcomes Assessments Phenotype Plasma Population Postmenopause Quality of life Quality-of-Life Assessment Records Recurrence Research Research Personnel Resources Risk Factors Sampling Serum Source Specimen Speed Surveys Survivors Techniques Translations Treatment outcome Tumor Tissue Ursidae Family Vial device Woman Women&apos s Health administrative database aging population biobank cancer diagnosis cancer invasiveness cancer recurrence cancer site cancer subtypes cancer therapy cohort cost demographics follow-up leukemia leukemia/lymphoma lifestyle factors malignant breast neoplasm melanoma molecular marker neoplasm registry outcome forecast population based pre-clinical programs randomized trial repository study population success survivorship tumor tumor heterogeneity

项目摘要

DESCRIPTION (provided by applicant): The Women's Health Initiative represents a large population-based sample of 161,000 postmenopausal US women. These women have been well-characterized in terms of demographics, diverse exposures, quality of life assessments and incidence of chronic diseases, including over 20,000 incident invasive cancers over a mean 12 years of follow-up. A biorepository maintains >5 million vials of serum, plasma and DNA, and over 93,000 women continue in active follow-up. WHI investigators seek to enhance opportunities for cancer survivorship studies, particularly those that recognize the import of molecular heterogeneity of tumors, by addressing two key limitations in the existing program. Specifically, we propose to; 1) collect information on cancer treatment, clinical outcomes (recurrence) and patient reported outcomes in women diagnosed with selected cancers (breast, colorectal, endometrial, lung, and ovarian cancers, lymphoma, leukemia, and melanoma, projected n=21,882) during WHI participation using Medicare linkages or direct medical record abstraction; and 2) collect paraffin-embedded tumor tissue from selected cancers (colorectal and ovarian cancers, melanoma, lymphoma, and breast and lung cancer subtypes, projected n=5,900). We will collect treatment and outcome data via linkage to Medicare datasets for cost efficiencies, whenever possible, and will pursue and evaluate methods to collect these data through access to other administrative databases. By enhancing the WHI database with cancer treatment and recurrence data, WHI will be a valuable resource to examine the effects of cancer diagnosis and treatment on overall health and quality of life in an aging cohort-one that represents the fastest growing population, bears the great cancer burden but has been under-represented in randomized trials. By supplementing the specimen repository with tumor specimens, the WHI Program will be able to support "up-to-date" phenotyping of cancers and contribute to our understanding of the molecular basis of cancer, its treatment and survival. We want to begin soon to ensure that a large and representative resource can be realized, because tumor tissue and records for cases diagnosed in the early period of the WHI will become increasingly difficult to obtain.

描述（由申请人提供）：妇女的健康计划代表了161,000个绝经后美国妇女的大量基于人群的样本。这些妇女在人口统计学，多样化的暴露，生活质量评估和慢性疾病的发生率方面都得到了很好的特征，包括在平均12年的随访中，包括20,000多个入侵性癌症。一个生物座位维持超过500万瓶血清，血浆和DNA，以及93,000多名女性继续进行积极的随访。研究人员试图通过解决现有计划中的两个关键局限性来提高癌症生存研究的机会，尤其是那些认识到肿瘤分子异质性的人。具体来说，我们建议； 1）收集有关癌症治疗，临床结局（复发）和患者报告的信息的信息，该妇女在使用Medicare链接或直接医疗记录的过程中预计，预计n = 21,882的妇女（乳腺癌，结肠直肠，子宫内膜，肺和卵巢癌，淋巴瘤，白血病和黑色素瘤）预计n = 21,882）和2）从选定的癌症（结直肠癌和卵巢癌，黑色素瘤，淋巴瘤以及乳腺癌和肺癌亚型）中收集石蜡包裹的肿瘤组织，预计n = 5,900）。我们将在可能的情况下通过与Medicare数据集的链接来收集治疗和结果数据，以提高成本效率，并将追求和评估通过访问其他管理数据库收集这些数据的方法。通过通过癌症治疗和复发数据增强WHI数据库，WHI将是一个有价值的资源，可以检查癌症诊断和治疗对代表增长最快人群的老龄化的总体健康和生活质量的影响，承担着巨大的癌症负担，但在随机试验中的代表性不足。通过用肿瘤标本补充样品存储库，WHI程序将能够支持癌症的“最新”表型，并有助于我们对癌症分子基础的理解，其治疗和生存。我们希望尽快开始，以确保能够实现大型和代表性的资源，因为在WHI早期诊断的病例和记录中，WHI越来越难以获得。